These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23153897)

  • 1. The effect of immediate postpartum depot medroxyprogesterone on early breastfeeding cessation.
    Brownell EA; Fernandez ID; Fisher SG; Howard CR; Ternullo SR; Lawrence RA; Duckett JW; Dozier AM
    Contraception; 2013 Jun; 87(6):836-43. PubMed ID: 23153897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of postpartum depot medroxyprogesterone administration among low-income mothers.
    Dozier AM; Nelson A; Brownell EA; Howard CR; Lawrence RA
    J Womens Health (Larchmt); 2014 Mar; 23(3):224-30. PubMed ID: 24443831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early experience with the contraceptive use of depot medroxyprogesterone acetate in an inner-city clinic population.
    Polaneczky M; Guarnaccia M; Alon J; Wiley J
    Fam Plann Perspect; 1996; 28(4):174-8. PubMed ID: 8853283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The discordance between planned use and actual receipt of immediate postpartum depot medroxyprogesterone among low-income women.
    Brownell EA; Lussier MM; Dozier AM; Howard CR; Fisher SG; Duckett JW; Lawrence RA; Fernandez ID
    Breastfeed Med; 2014; 9(6):290-3. PubMed ID: 24893264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Association between Immediate Postpartum Depot Medroxyprogesterone Acetate Use and Postpartum Depressive Symptoms.
    Ross CM; Shim JY; Stark EL; Wisner KL; Miller ES
    Am J Perinatol; 2023 Dec; 40(16):1765-1769. PubMed ID: 34775585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormonal contraceptive use and discontinuation among HIV-infected women in Uganda and Zimbabwe.
    Bengtson A; Kwok C; Salata RA; Byamugisha J; Chipato T; Rwambuya S; Moyo P; Morrison CS
    J Acquir Immune Defic Syndr; 2013 Aug; 63(4):506-13. PubMed ID: 23572011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone mineral density in long-term depot medroxyprogesterone acetate acceptors.
    Taneepanichskul S; Intaraprasert S; Theppisai U; Chaturachinda K
    Contraception; 1997 Jul; 56(1):1-3. PubMed ID: 9306024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Body weight and body composition of depot medroxyprogesterone acetate users.
    Dal'Ava N; Bahamondes L; Bahamondes MV; Bottura BF; Monteiro I
    Contraception; 2014 Aug; 90(2):182-7. PubMed ID: 24780631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of Cyclofem in the treatment of depot medroxyprogesterone acetate induced amenorrhea.
    Piya-Anant M; Koetsawang S; Patrasupapong N; Dinchuen P; d'Arcangues C; Piaggio G; Pinol A
    Contraception; 1998 Jan; 57(1):23-8. PubMed ID: 9554247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of depot medroxyprogesterone acetate contraception and incidence of bone fracture.
    Lanza LL; McQuay LJ; Rothman KJ; Bone HG; Kaunitz AM; Harel Z; Ataher Q; Ross D; Arena PL; Wolter KD
    Obstet Gynecol; 2013 Mar; 121(3):593-600. PubMed ID: 23635623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety of subcutaneously administered depot medroxyprogesterone acetate (104mg/0.65mL): A systematic review.
    Dragoman MV; Gaffield ME
    Contraception; 2016 Sep; 94(3):202-15. PubMed ID: 26874275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human vaginal histology in long-term users of the injectable contraceptive depot-medroxyprogesterone acetate.
    Bahamondes MV; Castro S; Marchi NM; Marcovici M; Andrade LA; Fernandes A; Bahamondes L
    Contraception; 2014 Aug; 90(2):117-22. PubMed ID: 24613369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early weight gain related to later weight gain in adolescents on depot medroxyprogesterone acetate.
    Bonny AE; Secic M; Cromer B
    Obstet Gynecol; 2011 Apr; 117(4):793-797. PubMed ID: 21422849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weight and body fat changes in postpartum depot-medroxyprogesterone acetate users.
    Nyirati CM; Habash DL; Shaffer LE
    Contraception; 2013 Jul; 88(1):169-76. PubMed ID: 23177262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interest in self-administration of subcutaneous depot medroxyprogesterone acetate in the United States.
    Upadhyay UD; Zlidar VM; Foster DG
    Contraception; 2016 Oct; 94(4):303-13. PubMed ID: 27326938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone density in women receiving depot medroxyprogesterone acetate for contraception.
    Cundy T; Evans M; Roberts H; Wattie D; Ames R; Reid IR
    BMJ; 1991 Jul; 303(6793):13-6. PubMed ID: 1830502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depo Provera. Position paper on clinical use, effectiveness and side effects.
    Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
    Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changing depot medroxyprogesterone acetate access at a faith-based institution.
    Guiahi M; McNulty M; Garbe G; Edwards S; Kenton K
    Contraception; 2011 Sep; 84(3):280-4. PubMed ID: 21843694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density.
    Kaunitz AM; Darney PD; Ross D; Wolter KD; Speroff L
    Contraception; 2009 Jul; 80(1):7-17. PubMed ID: 19501210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The long-term growth and development of children exposed to Depo-Provera during pregnancy or lactation.
    Pardthaisong T; Yenchit C; Gray R
    Contraception; 1992 Apr; 45(4):313-24. PubMed ID: 1387602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.